Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term

Merit Medical Systems (MMSI), a medical device company specializing in peripheral and cardiac intervention products, is identified by Zacks as a top growth stock, holding a #2 (Buy) Rank, an 'A' VGM Score, and a 'B' Growth Style Score. The firm projects 4.9% year-over-year earnings growth for MMSI, supported by a recent upward revision of its fiscal 2025 consensus earnings estimate to $3.63 per share and a historical average earnings surprise of +12.9%, positioning it as a strong consideration for growth-oriented portfolios.

Analysis

Merit Medical Systems (MMSI), a provider of peripheral and cardiac intervention products, has been identified with strong growth characteristics according to a proprietary rating system. The company holds a #2 (Buy) rank, supported by a composite 'A' for Value, Growth, and Momentum (VGM) and a 'B' for its Growth score specifically. This positive outlook is underpinned by a forecast for 4.9% year-over-year earnings growth in the current fiscal year. Furthermore, analyst sentiment for future performance appears to be improving, as evidenced by an upward earnings estimate revision for fiscal 2025 within the last 60 days. This revision has increased the consensus earnings per share estimate by $0.03 to $3.63. The company also has a demonstrated history of outperforming expectations, boasting an average positive earnings surprise of 12.9%, which suggests a pattern of conservative guidance or consistent operational over-delivery.

Key Decisions for Investors

• Given the combination of a 'Buy' rating, positive earnings estimate revisions, and a strong Growth Score, investors with a growth-oriented mandate should consider MMSI a candidate for their short list, pending further due diligence.
• Investors should monitor upcoming earnings announcements to see if the company's track record of delivering an average earnings surprise of +12.9% continues, as sustained outperformance would reinforce the current bullish thesis.
• The upward revision of the fiscal 2025 consensus EPS to $3.63 provides a key benchmark; any subsequent revisions to this figure will be a critical indicator of evolving analyst sentiment and the company's forward-looking prospects.